Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.38% | 4.12% | -375.94% | 129.09% | -79.92% |
| Total Depreciation and Amortization | 5.41% | 7.25% | -7.88% | -0.79% | 0.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.46% | 77.50% | 149.24% | -189.49% | 288.88% |
| Change in Net Operating Assets | 301.31% | -142.91% | 139.21% | -821.66% | -126.55% |
| Cash from Operations | 50.00% | -76.98% | 55.44% | -7.87% | -373.41% |
| Capital Expenditure | 93.75% | -1,100.00% | 93.92% | -2.81% | 24.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3,487.85% | 96.59% | -171.13% | 263.84% | -90,757.14% |
| Cash from Investing | 3,383.55% | 96.48% | -171.21% | 263.40% | -88,597.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -92.86% | -- | -- | 568.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -92.86% | -99.00% | -82.48% | 568.23% |
| Foreign Exchange rate Adjustments | -153.54% | -14.66% | -96.45% | 2,336.08% | 2,014.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 274.07% | 58.99% | -232.43% | 176.79% | -1,199.02% |